Efficacy and safety of travoprost 0.004%/timolol 0.5% fixed combination as transition therapy in patients previously on prostaglandin analog monotherapy

Purpose To assess the safety and efficacy of transitioning patients whose intraocular pressure (IOP) had been insufficiently controlled on prostaglandin analog (PGA) monotherapy to treatment with travoprost 0.004%/timolol 0.5% fixed combination with benzalkonium chloride (TTFC). Methods This prospective, multicenter, open-label, historical controlled, single-arm study transitioned patients who had primary open-angle glaucoma, pigment dispersion glaucoma, or ocular hypertension and who required further IOP reduction from PGA monotherapy to once-daily treatment with TTFC for 12 weeks. IOP and safety (adverse events, corrected distance visual acuity, and slit-lamp biomicroscopy) were assessed at baseline, week 4, and week 12. A solicited ocular symptom survey was administered at baseline and at week 12. Patients and investigators reported their medication preference at week 12. Results Of 65 patients enrolled, 43 had received prior travoprost therapy and 22 had received prior nontravoprost therapy (n = 18, bimatoprost; n = 4, latanoprost). In the total population, mean IOP was significantly reduced from baseline (P = 0.000009), showing a 16.8% reduction after 12 weeks of TTFC therapy. In the study subgroups, mean IOP was significantly reduced from baseline to week 12 (P = 0.0001) in the prior travoprost cohort (19.0% reduction) and in the prior nontravoprost cohort (13.1% reduction). Seven mild, ocular, treatment-related adverse events were reported. Of the ten ocular symptom questions, eight had numerically lower percentages with TTFC compared with prior PGA monotherapy and two had numerically higher percentages with TTFC (dry eye symptoms and ocular stinging/burning). At week 12, TTFC was preferred over prior therapy for 84.2% of patients (48 of 57) by the patients themselves, and for 94.7% of patients (54 of 57) by their physicians. Conclusion When TTFC replaced PGA monotherapy in patients whose IOP had been uncontrolled, the outcome was a significant reduction in IOP and an acceptable safety and tolerability profile. Most patients and investigators preferred TTFC to prior PGA monotherapy.

[1]  Y. Kitazawa,et al.  Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy , 2011, Eye.

[2]  F. M. Muñoz Negrete,et al.  Travoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5% , 2011, Advances in therapy.

[3]  Kuldev Singh,et al.  Medical management of glaucoma: Principles and practice , 2011, Indian journal of ophthalmology.

[4]  I. Krolo,et al.  Safety and efficacy of monotherapy change to fixed combination (travoprost 0.004%/timolol 0.5%) in 6 months follow up period. , 2010, Acta clinica Croatica.

[5]  L. Rossetti,et al.  Comparison of Travoprost and Bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combination. , 2010, American journal of ophthalmology.

[6]  S. Suić,et al.  Comparison of evening and morning dosing of travoprost 0.004%/timolol 0.5% fixed combination in 6 month period. , 2010, Collegium Antropologicum.

[7]  A. Konstas,et al.  24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma , 2010, Eye.

[8]  J. A. Stewart,et al.  Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy , 2010, Clinical ophthalmology.

[9]  S. Miglior,et al.  Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension , 2009, Clinical ophthalmology.

[10]  C. Tinelli,et al.  Switching from concomitant latanoprost 0.005% and timolol 0.5% to a fixed combination of travoprost 0.004%/timolol 0.5% in patients with primary open-angle glaucoma and ocular hypertension: a 6-month, multicenter, cohort study , 2009, Expert opinion on pharmacotherapy.

[11]  A. Konstas,et al.  Intraocular pressure control over 24 hours using travoprost and timolol fixed combination administered in the morning or evening in primary open‐angle and exfoliative glaucoma , 2009, Acta ophthalmologica.

[12]  A. Konstas,et al.  Twenty-four-hour intraocular pressure control with the travoprost/timolol maleate fixed combination compared with travoprost when both are dosed in the evening in primary open-angle glaucoma , 2008, British Journal of Ophthalmology.

[13]  E. Sullivan,et al.  Pooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5% , 2007, Clinical ophthalmology.

[14]  R. Allan.  The placebo effect. , 2006, Clinical medicine.

[15]  R. Andrew,et al.  A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. , 2006, European journal of ophthalmology.

[16]  J. Schuman,et al.  Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. , 2005, American journal of ophthalmology.

[17]  John Samples,et al.  The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. , 2005, American journal of ophthalmology.

[18]  S. Andrade.  Compliance in the real world. , 1998, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.